JP2020527174A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527174A5
JP2020527174A5 JP2020523235A JP2020523235A JP2020527174A5 JP 2020527174 A5 JP2020527174 A5 JP 2020527174A5 JP 2020523235 A JP2020523235 A JP 2020523235A JP 2020523235 A JP2020523235 A JP 2020523235A JP 2020527174 A5 JP2020527174 A5 JP 2020527174A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
heterocycloalkyl
haloalkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523235A
Other languages
English (en)
Japanese (ja)
Other versions
JP7159307B2 (ja
JP2020527174A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042128 external-priority patent/WO2019014618A1/en
Publication of JP2020527174A publication Critical patent/JP2020527174A/ja
Publication of JP2020527174A5 publication Critical patent/JP2020527174A5/ja
Application granted granted Critical
Publication of JP7159307B2 publication Critical patent/JP7159307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523235A 2017-07-13 2018-07-13 Atrキナーゼの複素環式阻害剤 Active JP7159307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531951P 2017-07-13 2017-07-13
US62/531,951 2017-07-13
PCT/US2018/042128 WO2019014618A1 (en) 2017-07-13 2018-07-13 HETEROCYCLIC INHIBITORS OF KINASE ATR

Publications (3)

Publication Number Publication Date
JP2020527174A JP2020527174A (ja) 2020-09-03
JP2020527174A5 true JP2020527174A5 (enExample) 2021-08-12
JP7159307B2 JP7159307B2 (ja) 2022-10-24

Family

ID=64998660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523235A Active JP7159307B2 (ja) 2017-07-13 2018-07-13 Atrキナーゼの複素環式阻害剤

Country Status (24)

Country Link
US (3) US10392376B2 (enExample)
EP (1) EP3651768B1 (enExample)
JP (1) JP7159307B2 (enExample)
KR (1) KR102676822B1 (enExample)
CN (2) CN117466884A (enExample)
AU (1) AU2018301696B8 (enExample)
CA (1) CA3069693A1 (enExample)
DK (1) DK3651768T3 (enExample)
ES (1) ES2974334T3 (enExample)
FI (1) FI3651768T3 (enExample)
HR (1) HRP20240368T1 (enExample)
HU (1) HUE066043T2 (enExample)
IL (1) IL271930B (enExample)
LT (1) LT3651768T (enExample)
MX (1) MX2020000386A (enExample)
NZ (1) NZ761374A (enExample)
PH (1) PH12020500072A1 (enExample)
PL (1) PL3651768T3 (enExample)
PT (1) PT3651768T (enExample)
RS (1) RS65466B1 (enExample)
SI (1) SI3651768T1 (enExample)
SM (1) SMT202400106T1 (enExample)
WO (1) WO2019014618A1 (enExample)
ZA (1) ZA202000148B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
LT3651768T (lt) 2017-07-13 2024-04-25 Board Of Regents, The University Of Texas System Heterocikliniai atr kinazės inhibitoriai
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
JP7235338B2 (ja) * 2017-09-08 2023-03-08 ニューウェーブ・ファーマスーティカル・インコーポレイテッド Atr阻害剤としての置換ピロロピリジン
WO2019178590A1 (en) * 2018-03-16 2019-09-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of atr kinase
EP3856743A4 (en) * 2018-09-27 2022-06-15 Fochon Pharmaceuticals, Ltd. SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2020244613A1 (zh) * 2019-06-06 2020-12-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021238999A1 (zh) 2020-05-29 2021-12-02 深圳市瓴方生物医药科技有限公司 氟代吡咯并吡啶类化合物及其应用
US20230339927A1 (en) * 2020-07-03 2023-10-26 Antengene Discovery Limited Atr inhibitors and uses thereof
CN116848113A (zh) * 2021-02-10 2023-10-03 南京再明医药有限公司 作为hpk1抑制剂的双环类化合物及其应用
AU2022271549A1 (en) * 2021-05-12 2023-11-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Sulfoximine-containing atr inhibitor compound
WO2022262143A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US20110034454A1 (en) * 2006-01-11 2011-02-10 Allan Paul Dishington Morpholino pyrimidine derivatives and their use in therapy
WO2008023159A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP2010503650A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性疾患の治療のための、pi3kおよびmtor阻害剤としての2−ベンズイミダゾリル−6−モルホリノ−4−ピペリジン−4−イルピリミジン誘導体
KR20100016431A (ko) 2007-04-12 2010-02-12 에프. 호프만-라 로슈 아게 약학적 화합물
US20080292588A1 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
AU2008273889B2 (en) 2007-07-09 2012-03-08 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP2176238B1 (en) 2007-07-09 2012-04-18 AstraZeneca AB Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
ES2535116T3 (es) 2010-03-04 2015-05-05 Cellzome Limited Derivados de urea sustituida con morfolino como inhibidores de mtor
EP2569289A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
TR201807740T4 (tr) 2012-12-07 2018-06-21 Vertex Pharma ATR kinaz inhibitörü olarak 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid.
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
SI3152212T1 (sl) 2014-06-05 2020-06-30 Vertex Pharmaceuticals Inc. Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
KR102569226B1 (ko) 2014-10-13 2023-08-22 아트린 파마슈티컬스 엘엘씨 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
LT3651768T (lt) 2017-07-13 2024-04-25 Board Of Regents, The University Of Texas System Heterocikliniai atr kinazės inhibitoriai
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
WO2019178590A1 (en) 2018-03-16 2019-09-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of atr kinase

Similar Documents

Publication Publication Date Title
JP2020527174A5 (enExample)
HRP20240368T1 (hr) Heterociklički inhibitori atr kinaze
JP7392096B2 (ja) Fgfr阻害剤としての置換三環式化合物
AU2005278292B2 (en) Novel substituted imidazole derivatives
KR101110530B1 (ko) 증식성 질환의 치료에 유용한 키나제 억제제
JP2020147592A (ja) Fgfr4阻害剤としての二環式複素環
DK2719699T3 (en) Triazolopyraziner particular, compositions thereof and methods of use thereof
WO2019183364A1 (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
RU2018138471A (ru) Гетероциклические соединения в качестве ингибиторов киназы RET
CA3054161A1 (en) Isoquinolines as inhibitors of hpk1
JP2009538825A5 (enExample)
WO2016203404A1 (en) Compounds and compositions for inhibiting the activity of shp2
KR20150068956A (ko) 세린/트레오닌 키나아제 억제제
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
RU2017138100A (ru) Имидазолонилхинолины и их применение в качестве ингибиторов киназы атм
HRP20170349T1 (hr) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
CA3198809A1 (en) Heterocyclic spiro compounds and methods of use
JP2013531684A5 (enExample)
KR20130043198A (ko) 키나제 억제제로서 치환된 이미다조퀴놀린 유도체
JP6888006B2 (ja) Mnk1およびmnk2を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
AU2013225533A1 (en) Amido spirocyclic amide and sulfonamide derivatives
CN102399233A (zh) PI3K和mTOR双重抑制剂类化合物
JP2014510037A5 (enExample)
EP4237086A1 (en) Heterocyclic spiro compounds and methods of use
KR20140103972A (ko) 세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체